Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29187943 | 1.00 | PDE4B (0.49) | PDE4BL3MBTL1KMT2ANPSR1PREP | |
| SCHEMBL3070355 | 1.00 | PDE4B (0.49) | PDE4BL3MBTL1KMT2ANPSR1PREP | |
| SCHEMBL3084195 | 1.00 | PDE4B (0.49) | PDE4BL3MBTL1KMT2ANPSR1PREP | |
| SCHEMBL3070357 | 1.00 | PDE4B (0.49) | PDE4BL3MBTL1KMT2ANPSR1PREP | |
| SCHEMBL3070354 | 1.00 | PDE4B (0.49) | PDE4BL3MBTL1KMT2ANPSR1PREP | |
| SCHEMBL16032213 | 0.92 | KLK7 (0.48) | PDE4BL3MBTL1KMT2ANPSR1PREP | |
| SCHEMBL16030781 | 0.92 | KLK7 (0.48) | PDE4BL3MBTL1KMT2ANPSR1PREP | |
| SCHEMBL16030780 | 0.92 | KLK7 (0.48) | PDE4BL3MBTL1KMT2ANPSR1PREP | |
| SCHEMBL16031358 | 0.92 | KLK7 (0.48) | PDE4BL3MBTL1KMT2ANPSR1PREP | |
| SCHEMBL23971172 | 0.89 | L3MBTL1 (0.49) | PDE4BL3MBTL1KMT2ANPSR1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | CHEK1, PDK1, CHEK2 | PDE4B 1073/4885L3MBTL1 1826/4885KMT2A 1568/4885 |
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | CHEK1, CHEK2, MCL1 | PDE4B 3034/4885L3MBTL1 388/4885KMT2A 74/4885 |
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | PDE4B 1175/4885L3MBTL1 3531/4885KMT2A 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.